KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder,
This document is hosted externally.
Unless the owner has removed it from the web, you can access the full document via its original URL:
https://www.eisai.com/news/2021/pdf/enews202124pdf.pdfUnless the owner has removed it from the web, you can access the full document via its original URL:
See similar contracts (2)
Alternatively, you can try searching for similar contracts:
